AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
110 hedge funds and large institutions have $368M invested in AVEO Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 32 closing their positions.
3,005% more call options, than puts
Call options by funds: $6.02M | Put options by funds: $194K
172% more capital invested
Capital invested by funds: $135M → $368M (+$233M)
103% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 32
92% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 12
43% more funds holding
Funds holding: 77 → 110 (+33)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
+$20.3M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$20M |
| 3 |
Man Group
London,
United Kingdom
|
+$18M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$16.9M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$32.5M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$28.3M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$13.7M |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$7.12M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$5.4M |
AVEO Hedge Fund Activity: Q4 2022 in Review
110 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q4 2022, worth a combined $368M — up 172% from $135M a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new AVEO positions and 32 closed out — a net gain of 33 holders — while 23 added to existing stakes and 12 trimmed.
The largest buyer was Nexpoint Asset Management, opening a new position worth an estimated $20.3M. The largest seller was NEA Management Company, exiting entirely with an estimated $32.5M sold.
- 110 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q4 2022, up from 77 in Q3 2022.
- Funds reported $368M of AVEO Pharmaceuticals, Inc. stock for Q4 2022, up 172% quarter-over-quarter.
- 65 funds opened new AVEO Pharmaceuticals, Inc. positions in Q4 2022 and 32 closed out, a net change of +33 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q4 2022 was Nexpoint Asset Management, an estimated $20.3M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q4 2022 was NEA Management Company, an estimated $32.5M sold.
Based on aggregated 13F filings for Q4 2022.